| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥6142.9B | ¥5797.0B | - |
| Operating Income | ¥338.6B | ¥359.0B | - |
| Profit Before Tax | ¥264.5B | ¥159.8B | - |
| Net Income | ¥143.4B | ¥71.8B | - |
| ROE | 1.5% | 0.8% | - |
OMRON Corporation's FY2026 Q3 (9-month cumulative) results show revenue of 614.3B yen (YoY +6.0%), operating income of 33.9B yen (YoY -5.7%), ordinary income of 26.5B yen, and net income of 14.3B yen (YoY +99.5%). The company achieved solid top-line growth driven by robust demand recovery in Industrial Automation Business (IAB), particularly from AI-related semiconductor and secondary battery sectors. However, operating profit declined due to gradual gross margin recovery and continued growth investments. Full-year guidance was revised upward for revenue to 855.0B yen (+6.6% YoY) while maintaining operating income forecast at 60.0B yen (+11.0% YoY), reflecting expectations for substantial Q4 profit improvement. ROE stands at 1.5%, significantly below historical levels, reflecting high tax and interest burdens alongside operational margin pressures.
Revenue growth of +6.0% YoY was primarily driven by the Industrial Automation Business (IAB), which grew +9.8% to 282.5B yen, capturing AI-related demand in semiconductor equipment and data center secondary battery investments. Data Solutions Business (DSB) expanded +19.3% to 37.6B yen as medical data utilization demand remained strong. Healthcare Business (HCB) was essentially flat at -0.6%, impacted by sluggish Chinese consumer spending and US tariff uncertainties, while Social Systems Business (SSB) grew modestly at +1.1% despite temporary demand pauses in renewable energy and rail sectors.
Operating profit declined -5.7% to 33.9B yen despite revenue growth, with operating margin contracting to 5.5% from 6.2% prior year. The margin compression stemmed from gross profit margin declining -1.3pt YoY due to inventory valuation losses, variable cost pressures, and product mix effects, partially offset by ongoing cost reduction initiatives. Continued growth investments in new product development (22 models released in FY2025) and sales expansion further weighed on profitability. Selling, general and administrative expenses increased +4.5B yen YoY, while R&D expenses rose +6.2B yen.
The substantial gap between ordinary income (26.5B yen) and net income (14.3B yen pre-tax equivalent 26.5B yen) reflects a high effective tax rate, with the tax burden coefficient at 0.542 (effective tax rate approximately 46%). The interest burden coefficient of 0.781 (EBT/EBIT) indicates significant financial costs are also constraining profitability. Despite these headwinds, net income nearly doubled YoY, though this improvement appears heavily influenced by non-operating and tax-related factors rather than core operational strength.
Non-recurring items include business portfolio optimization activities: discontinuation of payment terminal operations, sale of European automotive relay business, and manufacturing footprint restructuring in Healthcare. These structural changes are in progress but specific financial impacts were not disclosed in the quarter.
This represents a "revenue up, profit down" pattern driven by strong demand offset by margin compression and strategic investment costs.
Industrial Automation Business (IAB) is the core business, generating 282.5B yen revenue (46.0% of total) and 27.1B yen operating income in Q3 cumulative. Q3 quarterly revenue reached 101.1B yen (+10.4% YoY) while operating income was 9.7B yen (-13.7% YoY). The segment drove overall revenue growth, capturing global FA demand recovery and significant AI-related orders in semiconductor manufacturing equipment (sales +8% YoY in H2) and secondary battery production for data centers (+37% YoY). Order intake surged to 1.20x prior year level. However, operating margin declined due to gross margin pressures and continued investment in new product launches. Full-year segment targets are 396.0B yen revenue and 41.5B yen operating income.
Healthcare Business (HCB) contributed 115.0B yen revenue (18.7% of total) and 12.5B yen operating income in Q3 cumulative. Q3 quarterly results showed 41.3B yen revenue (+6.7% YoY) and 5.5B yen operating income (+0.3% YoY). While global blood pressure monitor markets remained solid, Chinese consumer weakness and US tariff uncertainties constrained growth. Operating profit declined -14.2% YoY cumulatively due to volume and margin pressures. Full-year targets are 145.0B yen revenue and 15.0B yen operating income.
Social Systems Business (SSB) generated 100.4B yen revenue (16.3% of total) and 15.8B yen operating income (+27.1% YoY) in Q3 cumulative, showing the highest margin improvement. However, Q3 quarterly performance weakened with 33.6B yen revenue (-5.1% YoY) and 3.7B yen operating income (-7.4% YoY) due to temporary demand pauses from early termination of residential renewable energy subsidies and delays in industrial projects. Full-year guidance was revised down by -5.0B yen revenue to 145.0B yen and -0.5B yen operating income to 19.5B yen.
Electronic and Mechanical Components Business (DMB) reported 83.1B yen revenue (+9.1% YoY) and 1.7B yen operating income (vs 0.2B yen prior year) in Q3 cumulative. Q3 quarterly results were 30.3B yen revenue (+11.9% YoY) and 0.8B yen operating income (+936.8% YoY). Semiconductor market expansion drove strong DC relay and high-frequency relay demand. Full-year operating income forecast was revised down by -1.5B yen to 2.5B yen despite revenue strength.
Data Solutions Business (DSB) achieved 37.6B yen revenue (+19.3% YoY) and 3.7B yen operating income (+76.7% YoY) in Q3 cumulative. Q3 quarterly performance showed 13.8B yen revenue (+21.8% YoY) and 1.9B yen operating income (+41.3% YoY). Subsidiary JMDC continued robust growth in medical data utilization services to pharmaceutical and insurance sectors. Full-year targets are 51.0B yen consolidated revenue and 5.0B yen operating income, with JMDC standalone projecting 50.5B yen revenue and 11.5B yen operating income.
Segment margin dispersion is material: DSB shows improving profitability driven by scalable software/data business model, while IAB margin compression reflects temporary cost headwinds offset by volume leverage. SSB demonstrates strong margin despite revenue headwinds. HCB faces margin pressures from geographical mix and market conditions.
Profitability: ROE 1.5% (prior year 0.8%), operating margin 5.5% (prior year 6.2%), net profit margin 2.3% (prior year 1.2%), ROIC 2.4% (management target 7-8%). ROE remains substantially below manufacturing sector standards despite YoY improvement, constrained by low asset turnover (0.424), conservative financial leverage (1.49x), and compressed net margins.
Cash Quality: Operating cash flow and free cash flow data not disclosed in available materials, preventing OCF/Net Income and FCF calculation. This represents a material information gap for earnings quality assessment.
Investment: Detailed CapEx and depreciation data not disclosed. Company continues growth investments including 22 new product releases in FY2025 and 9 planned for FY2026, with Q3 cumulative new product sales contributing approximately 15.0B yen. R&D expenses increased +6.2B yen YoY, indicating sustained commitment to innovation.
Financial Health: Equity ratio 55.8% (prior year end 59.6%), total assets 1,448.0B yen (+6.3% vs prior year end), net assets 972.3B yen (+4.1% vs prior year end). Current ratio not disclosed. The equity ratio remains solid but declined moderately due to asset expansion. Interest burden coefficient 0.781 suggests meaningful debt servicing costs relative to operating earnings.
Efficiency: Asset turnover 0.424 (annualized basis), inventory increased +31.9B yen vs prior year end due to business expansion and supply chain positioning. Specific working capital turnover metrics not disclosed.
DuPont 5-factor analysis reveals tax burden coefficient 0.542, interest burden coefficient 0.781, EBIT margin 5.5%, asset turnover 0.424, and financial leverage 1.49x. The primary ROE constraints are high effective tax rate (approximately 46%), significant interest costs, and compressed operating margins. These structural headwinds limit ROE despite adequate leverage and require operational improvements to achieve management's ROIC targets.
Operating cash flow, investing cash flow, and financing cash flow data were not disclosed in available XBRL or presentation materials, preventing quantitative cash flow analysis. This represents a critical information gap.
Based on balance sheet changes: Cash and equivalents increased +6.2B yen vs prior year end to modest levels. Inventory rose +31.9B yen, suggesting working capital consumption. Total assets expanded +86.2B yen with current assets +45.9B yen and non-current assets +40.3B yen, implying capital deployment into operations and potentially investments.
The absence of operating cash flow data prevents assessment of earnings quality through OCF/Net Income ratio, which is essential given the high reported payout ratio. Without visibility into free cash flow (Operating CF - CapEx), the sustainability of the planned 104 yen annual dividend cannot be objectively evaluated. Management maintains full-year dividend guidance at 52 yen per share (note: presentation indicates 52 yen fiscal year end, with 52 yen interim already paid, totaling 104 yen annually), but FCF coverage is unverifiable.
Cash generation assessment: Cannot be determined - requires disclosure of operating cash flow statement.
Ordinary income of 26.5B yen compared to net income of 14.3B yen reflects substantial tax burden, with an effective tax rate near 46% (tax burden coefficient 0.542). This is elevated relative to typical Japanese corporate tax rates and warrants clarification of temporary vs. structural tax factors. The gap between operating income (33.9B yen) and ordinary income (26.5B yen) indicates net non-operating costs of approximately -7.4B yen, primarily interest expenses given the interest burden coefficient of 0.781.
Non-operating items include portfolio restructuring activities: payment terminal business wind-down, European automotive relay business divestiture, and Healthcare manufacturing footprint consolidation. Specific gains/losses from these activities were not quantified in Q3 results. These are non-recurring in nature but the financial impact magnitude is unclear.
Non-operating income relative to revenue is approximately -1.2% (net non-operating costs of -7.4B yen on 614.3B yen revenue), which is material but not unusual for a manufacturing conglomerate with global operations and financing activities.
A critical earnings quality concern exists regarding cash backing. Operating cash flow data is unavailable, preventing OCF/Net Income comparison. Given net income of 14.3B yen over 9 months against inventory build of +31.9B yen and planned dividends of approximately 104 yen per share (requiring roughly 23B yen assuming approximately 220M shares), the cash generation profile requires verification. The calculated payout ratio of 149.6% based on XBRL data (104 yen dividend / net income per share) signals potential sustainability risk unless operating cash flow significantly exceeds net income or the company draws on reserves.
Accrual quality cannot be assessed without cash flow statement disclosure. The substantial inventory increase may indicate timing differences between reported profits and cash realization, though it could also reflect strategic positioning for anticipated Q4 demand surge.
Full-year FY2026 guidance: Revenue 855.0B yen (+6.6% YoY), operating income 60.0B yen (+11.0% YoY), net income 29.0B yen (+78.2% YoY), dividend 52 yen per share (fiscal year end, following 52 yen interim for 104 yen annual total).
Q3 cumulative progress rates against full-year guidance: Revenue 71.8% (standard 75.0%, -3.2pt behind), operating income 56.4% (standard 75.0%, -18.6pt behind). The revenue shortfall is modest and likely attributable to seasonal patterns. The operating income shortfall is more significant, requiring substantial Q4 profit contribution.
Implied Q4 quarterly performance: Revenue 240.7B yen (vs Q3 quarterly 220.8B yen, +9.0% sequential), operating income 26.1B yen (vs Q3 quarterly 16.1B yen, +62.1% sequential, +80.0B yen YoY absolute). Management explicitly forecasts Q4 operating income of 26.1B yen (+44% YoY) driven by continued revenue expansion and gross margin improvement.
Revenue guidance was revised upward by +10.0B yen from prior forecast, incorporating Q4 foreign exchange assumptions (USD 150.0 yen, EUR 175.0 yen, CNY 21.5 yen) and stronger-than-expected IAB demand continuation. Operating income guidance was maintained at 60.0B yen, reflecting confidence in Q4 margin recovery from pricing actions, cost reduction initiatives, and operating leverage.
Key revision drivers: IAB segment outperformance from AI-related semiconductor and secondary battery orders exceeding prior expectations, with order backlog at 1.20x prior year. Partially offset by SSB downward revision of -5.0B yen revenue and -0.5B yen operating income due to renewable energy subsidy timing and project delays, and DMB operating income reduction of -1.5B yen despite revenue strength.
Progress rate deviation analysis: The Q4 implied operating income surge of +62% sequential represents a sharp inflection after nine months of margin compression. Management attributes this to completion of gross margin recovery measures, operating leverage from volume growth, new product contribution (15.0B yen cumulative, accelerating in Q4), and controlled fixed cost growth. Key assumptions include: (1) IAB gross margin expansion from product mix improvement and cost reduction completion, (2) volume leverage across segments, (3) FX stability at guided rates, (4) successful new product ramp (particularly Data Flow Controller DX1 exceeding plan by +30% revenue, +106% orders).
Risks to guidance achievement include FX sensitivity (USD +/-1 yen impacts operating income by +/-0.1B yen, EUR by +/-0.3B yen, CNY by +/-1.0B yen per 0.1 yen), gross margin recovery pace, and Q4 demand realization in IAB's AI-related pipeline.
Annual dividend of 104 yen per share (52 yen interim paid, 52 yen fiscal year-end planned) maintained from initial guidance. Based on Q3 cumulative net income of 14.3B yen over 9 months and estimated share count, the calculated payout ratio is 149.6%, which exceeds earnings and raises sustainability concerns.
However, this calculation requires context: (1) Management explicitly maintains 104 yen annual dividend guidance alongside full-year net income forecast of 29.0B yen, implying a policy payout ratio near 36% on full-year earnings, (2) Q3 cumulative earnings were depressed by one-time factors and margin compression that are expected to reverse in Q4, and (3) historical dividend policy and actual cash reserves are not disclosed in available materials.
Without operating cash flow and free cash flow data, FCF dividend coverage cannot be assessed. The sustainability of the dividend depends critically on: (1) achievement of Q4 profit guidance (requiring net income of approximately 14.7B yen in Q4 alone to reach 29.0B yen full-year), and (2) operating cash generation substantially exceeding reported net income to cover dividends plus working capital and capex requirements.
Share buyback activity was not disclosed in Q3 materials. Total return ratio cannot be calculated.
Management's maintained dividend guidance despite elevated interim payout ratio suggests confidence in Q4 earnings recovery and/or sufficient cash reserves. However, investors should monitor Q4 results and FY2027 dividend policy closely, as sustained earnings pressure could necessitate dividend adjustment if cash flow does not support current levels.
ROE of 1.5% and ROIC of 2.4% are both substantially below management's stated ROIC target of 7-8%, indicating capital allocation efficiency requires improvement. The combination of low capital returns and potentially unsustainable payout ratio (on interim basis) represents a shareholder return risk.
Near-term: Q4 FY2026 earnings release (May 2025) will be critical to validate management's forecast for substantial profit inflection, with implied operating income of 26.1B yen required to meet guidance. Success hinges on IAB gross margin recovery, AI-related order backlog conversion, and new product contribution acceleration. Foreign exchange stability at assumed rates (USD 150, EUR 175, CNY 21.5) is essential.
New product ramp of Data Flow Controller DX1 and other recent launches achieving +30% revenue outperformance vs. plan provides potential upside catalyst. IAB order backlog at 1.20x prior year converting to revenue in Q4 and into FY2027 represents positive momentum.
Social Systems Business recovery from temporary renewable energy and rail sector pauses as projects resume and subsidy clarity emerges. Healthcare market stabilization in China and US tariff resolution could remove headwinds.
Long-term: Structural growth in AI-related semiconductor manufacturing equipment and data center infrastructure driving sustained IAB demand through multi-year investment cycles. Company's positioning in advanced inspection equipment (AXI sales +182% YoY) and secondary battery production automation (+37% YoY) aligns with secular trends.
Business portfolio optimization completion (payment terminal exit, automotive relay divestiture, Healthcare footprint restructuring) simplifying operations and potentially improving margin structure. Timeline and financial impact require clarification.
Operating margin improvement initiatives targeting management's ROIC goal of 7-8% (vs current 2.4%). Key levers include gross margin expansion from new products and cost reduction, SG&A efficiency through indirect function JV (OMRON Transcosmos Process Innovation) and regional HQ consolidation, and revenue growth leverage. Achievement timeline uncertain but critical to shareholder value creation.
Expansion in Data Solutions Business (JMDC) as medical data utilization accelerates in pharmaceutical and insurance sectors, offering high-margin revenue growth potential. FY2026 JMDC standalone targets of 50.5B yen revenue and 11.5B yen operating income (22.8% margin) demonstrate strong business model economics.
Industry Position (Reference - Proprietary Analysis):
Profitability: ROE 1.5% substantially below manufacturing sector median of 5.0% (2025-Q3, n=98 companies, interquartile range 2.9%-8.1%). Operating margin 5.5% also trails sector median of 8.3% (IQR 4.8%-12.6%), positioning OMRON in the lower quartile. Net profit margin 2.3% compares unfavorably to sector median of 6.3% (IQR 3.2%-9.0%). ROIC 2.4% vs. sector median 5.0% (IQR 3.0%-10.0%) indicates capital efficiency materially below peer average. These metrics reflect the margin compression and elevated tax/interest burdens constraining current profitability.
Financial Health: Equity ratio 55.8% is below sector median of 63.8% (IQR 49.5%-74.7%) but remains within the interquartile range, indicating adequate though not exceptional financial stability. Financial leverage of 1.49x is modestly below sector median of 1.53x (IQR 1.31-1.85), suggesting conservative balance sheet structure is not the primary ROE constraint.
Efficiency: Asset turnover 0.424 is significantly below sector median of 0.58 (IQR 0.42-0.66), indicating lower asset productivity. This positions OMRON near the bottom quartile for capital intensity, reflecting the manufacturing-intensive Industrial Automation core business.
Growth: Revenue growth of +6.0% YoY substantially exceeds sector median of +2.7% (IQR -1.9% to +7.9%), placing OMRON in the top quartile for top-line expansion. However, the disconnect between revenue growth and profit performance (operating income -5.7%) contrasts with peer ability to convert sales into earnings.
Reference Context: Industry classification = Manufacturing sector, sample size n=98 companies for most metrics as of 2025-Q3, source = Proprietary analysis of publicly available earnings data. Comparisons reflect prior fiscal periods industry medians. These benchmarks provide reference context for relative performance evaluation but do not constitute investment recommendations.
OMRON's current positioning shows strong revenue momentum exceeding peer median but profitability and capital efficiency in bottom quartiles. The strategic priority is margin recovery to close the gap with sector profitability norms while sustaining top-line growth.
Margin Recovery Execution Risk: Gross profit margin declined -1.3pt YoY in Q3 cumulative despite revenue growth, driven by inventory valuation losses, product mix effects, and cost pressures. Management forecasts Q4 margin inflection requiring successful execution of pricing actions, cost reduction initiatives (variable cost "CD" programs), and favorable product mix from new launches. If these measures fall short, implied Q4 operating income of 26.1B yen (+62% sequential) will not materialize, jeopardizing full-year guidance and dividend sustainability. Quantified risk: Each 1pt shortfall in gross margin improvement equates to approximately 6B yen annual operating income impact at current revenue run-rate.
Foreign Exchange and Geopolitical Exposure: Q4 guidance assumes USD 150.0, EUR 175.0, CNY 21.5 yen. Actual FX volatility or deviation creates material earnings risk with sensitivity of USD +/-1 yen = +/-0.1B yen operating income, EUR +/-1 yen = +/-0.3B yen, CNY +/-0.1 yen = +/-1.0B yen. Healthcare Business faces ongoing uncertainty from US tariff policies (unquantified impact noted) and Chinese consumer weakness (blood pressure monitor market flat, circulatory/respiratory products soft). Social Systems Business exposure to renewable energy subsidy policy changes and rail investment cycles demonstrated by -5.0B yen revenue guidance cut. Geographic and policy risks are diversified but aggregated impact significant given 60%+ revenue from outside Japan.
Dividend Sustainability and Capital Efficiency: Calculated payout ratio of 149.6% on Q3 cumulative earnings creates sustainability question despite management's maintained 104 yen annual dividend guidance. Absent disclosed operating cash flow data, ability to fund dividends, working capital (inventory +31.9B yen), capex, and growth investments from cash generation is unverifiable. If Q4 earnings fall short of implied 14.7B yen net income requirement or operating cash flow lags reported profits, dividend policy may require reassessment in FY2027. Simultaneously, ROE 1.5% and ROIC 2.4% remain far below management's 7-8% ROIC target and cost of capital, indicating value destruction on incremental investments. Extended period of sub-par returns could pressure valuation and limit strategic flexibility. Quantified risk: Failure to achieve ROIC target implies continued bottom-quartile peer positioning and potential for rating/valuation multiple compression.
OMRON's Q3 FY2026 earnings demonstrate a critical divergence between revenue momentum and profitability trends that defines the current investment proposition. The company successfully captured AI-driven demand expansion in semiconductor and data center secondary battery sectors, achieving +6.0% revenue growth that significantly exceeds manufacturing sector median of +2.7%. Industrial Automation Business order backlog at 1.20x prior year and +10.4% Q3 quarterly revenue growth validate strategic positioning in secular growth markets. However, this top-line success has not translated to profit growth, with operating income declining -5.7% and operating margin compressing to 5.5% vs. sector median of 8.3%. The profitability shortfall stems from three factors: (1) gross margin erosion from product mix, inventory valuation, and cost pressures reducing pricing power, (2) sustained growth investments in new products and market expansion prioritizing future positioning over near-term earnings, and (3) structural headwinds from high tax burden (46% effective rate) and interest costs. The critical question is whether management can execute the forecasted Q4 profit inflection (+62% sequential operating income growth) to validate that margin compression is cyclical rather than structural.
The earnings quality assessment is materially constrained by absence of operating cash flow disclosure, creating uncertainty around dividend sustainability and capital allocation effectiveness. The calculated 149.6% payout ratio on Q3 cumulative earnings conflicts with management's maintained 104 yen annual dividend guidance, which assumes full-year net income of 29.0B yen. This discrepancy will be resolved or exacerbated by Q4 results, making the upcoming quarterly report a critical validation point. Investors should note that even if full-year earnings guidance is achieved, ROE of 1.5% and ROIC of 2.4% position the company in the bottom quartile of manufacturing peers and far below management's stated 7-8% ROIC target. This capital efficiency gap indicates that growth investments and operational improvements must materially accelerate to generate acceptable shareholder returns, particularly given equity ratio of 55.8% providing financial flexibility for more aggressive capital deployment.
The forward outlook hinges on three key transitions: (1) conversion of strong IAB order backlog and new product pipeline into profitable revenue as gross margin recovery initiatives take effect in Q4 and FY2027, (2) stabilization of Healthcare and Social Systems segments as geopolitical uncertainties and policy headwinds subside, and (3) operating leverage realization as efficiency initiatives (indirect function JV, regional HQ consolidation, portfolio simplification) reduce fixed cost growth below revenue expansion. The company's exposure to multi-year AI infrastructure buildout provides meaningful growth visibility, but margin structure improvement is essential to translate this opportunity into shareholder value. Current valuation and capital allocation policy (dividend maintenance at elevated payout despite sub-par ROIC) suggest management confidence in earnings recovery, but execution risk is elevated given the magnitude of Q4 profit inflection required and structural profitability gap versus peers.
This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI analysis of PDF earnings presentation
OMRON Corporation announced results for the third quarter of the fiscal year ending March 2026. For the nine months of Q1–Q3 (April–December), revenue increased to 614.3 billion yen (YoY +6.0%), while operating income declined to 33.9 billion yen (YoY -5.7%). The full-year outlook was revised up for revenue to 855.0 billion yen (YoY +6.6%), maintaining growth, while operating income is kept unchanged at 60.0 billion yen (YoY +11.0%). In the Industrial Automation Business, revenue rose significantly on top of a recovery in global FA demand and wins related to AI-driven investments in semiconductors and secondary batteries for data centers, whereas profit fell below the prior year due to only a gradual recovery in gross margin and continued growth investments. For Q4, operating income is projected to rise substantially QoQ on revenue growth and improved profitability. Dividends are maintained at 52 yen at year-end, 104 yen for the full year. The company indicates a policy of continuing medium- to long-term growth investments while working to improve profitability.
In Q3 (October–December), revenue increased to 220.8 billion yen (YoY +7.7%), while operating income decreased to 16.1 billion yen (YoY -3.2%). Gross margin saw only a gradual recovery, and continued growth investments led to lower earnings. The full-year outlook for revenue was revised up by 10.0 billion yen from the previous forecast to 855.0 billion yen, while operating income remains at 60.0 billion yen. FX impact and business conditions for the Q4 period are incorporated. The Industrial Automation Business recorded significant revenue growth in Q3 with 101.1 billion yen (YoY +10.4%). Orders surged sharply on wins tied to AI-related demand (semiconductor equipment and storage batteries for data centers). For Q4, the company expects revenue to increase by +8% QoQ and gross margin to improve, projecting operating income of 26.1 billion yen (YoY +8.0 billion yen), turning to full-year profit growth. Planned dividend is 52 yen at year-end (104 yen for the full year), unchanged from the initial forecast. ROE and ROIC are both expected to be around 3%.
For FY2025 full year, the company plans revenue of 855.0 billion yen (YoY +6.6%), operating income of 60.0 billion yen (YoY +11.0%), and net income attributable to owners of the parent of 29.0 billion yen (YoY +78.2%). The Industrial Automation Business is expected to continue outperforming the prior assumption on sustained wins for AI demand in the semiconductor and secondary battery industries. For the Q4 period, revenue is expected at 240.7 billion yen (+8% QoQ) and operating income at 26.1 billion yen (+44% YoY), implying a substantial profit increase. The Healthcare Business and Data Solutions Business are also trending solidly, and while continuing growth investments with a medium- to long-term view, profitability is set to steadily improve, turning to profit growth in Q4.
In Q3, revenue increased on recovery of the customer base and wins in AI-related demand, but profit declined due to lower gross margin and continued growth investments. For the full year, revenue was revised upward, incorporating FX impact and business conditions in Q4. Even while continuing medium- to long-term growth investments, profitability is steadily improving, with a substantial profit increase anticipated in Q4. The Industrial Automation Business continues to outperform the prior assumption on the back of on-schedule new product releases and a sharp rise in order levels. The company will accelerate execution of various profitability measures to further improve the operating margin from next fiscal year onward.
Advance new product development and releases in the Industrial Automation Business as planned (22 models to be completed in FY25, 9 models planned for FY26). Full-year sales of new products are expected to be approximately 15.0 billion yen. Capture capital investments driven by expanding AI demand in the semiconductor industry (leading-edge semiconductors and manufacturing equipment) and in secondary batteries for data centers. Semiconductor industry sales are expected to be +8% YoY in H2, AXI (X-ray board inspection equipment) sales +182% YoY, and secondary battery industry sales +37% YoY, all showing significant increases. Launch the new controller “Data Flow Controller DX1” in September 2025. It enables easy data collection and visualization from existing equipment, promoting data utilization at manufacturing sites. Cumulative sales are +30% versus plan, and orders are +106% versus plan. Optimize the business portfolio by winding down the payment terminal business, selling the European automotive relay business, and reorganizing manufacturing sites in the Healthcare Business. Promote efficiency in selling, general and administrative expenses. In Japan, improve efficiency of indirect operations through a JV (OMRON Transcosmos Process Innovation); overseas, dissolve area headquarters companies (Korea, Asia, the Americas, Europe).
Gross margin only recovered gradually, declining by -1.3pt YoY in Q3. Inventory valuation losses and the impact of variable cost reductions (CD) compressed margins. In the Social Systems Business, a temporary demand pause is expected in the renewable energy market and the railway industry (early termination of housing subsidies, delays in industrial project schedules, and deferred capital expenditures). In the Healthcare Business, uncertainty persists in North America due to tariff impacts, while in China, stagnant consumer spending keeps the blood pressure monitor market flat and cardiovascular/respiratory segments sluggish. FX assumptions for the Q4 period are USD/JPY 150.0, EUR/JPY 175.0, and CNY/JPY 21.5. If actual FX differs from assumptions, it will affect results (full-year FX sensitivity: approximately 1.2 billion yen in revenue and 0.1 billion yen in operating income per 1 yen move in USD; 0.7 billion yen in revenue and 0.3 billion yen in operating income per 1 yen move in EUR; 0.7 billion yen in revenue and 0.1 billion yen in operating income per 0.1 yen move in CNY). Fixed costs continue to rise YoY due to increases in personnel and expenses (for the nine months, SG&A +4.5 billion yen and R&D +6.2 billion yen). There is a risk that profitability improvement may lag while growth investments continue.